GLP-1 Therapies Show Strong Efficacy for Liver Fat and Inflammation
Background
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), formerly known as Non-alcoholic Fatty Liver Disease (NAFLD), and its more severe inflammatory form, Metabolic Dysfunction-associated Steatohepatitis (MASH), formerly NASH, are rapidly growing global health concerns. These conditions are closely linked to obesity, type 2 diabetes, and metabolic syndrome, often progressing to cirrhosis, liver failure, and hepatocellular carcinoma. While lifestyle interventions are foundational, effective pharmacological treatments remain limited. This systematic review and meta-analysis aimed to comprehensively evaluate the efficacy of GLP-1-based therapies across multiple studies for improving MASLD and MASH outcomes.
Results
The meta-analysis revealed significant benefits of GLP-1-based therapies across multiple liver health parameters. Treatment with GLP-1 RAs led to a remarkable 2.8-fold higher odds of achieving MASH resolution without worsening of fibrosis compared to placebo (p<0.001). Liver fat content, assessed by MRI-PDFF, showed an average 38% relative reduction from baseline in the GLP-1 RA groups, significantly greater than the 12% reduction observed in control groups (p<0.001). The most impactful finding was that GLP-1 receptor agonists achieved MASH resolution in 52% of treated patients, compared to only 21% in placebo groups, demonstrating a substantial clinical impact. Furthermore, a significant proportion of patients (31%) treated with GLP-1 RAs experienced at least a one-stage improvement in liver fibrosis, versus 15% in the control arms (p<0.001), indicating a potential to reverse liver scarring. Reductions in liver enzymes, such as ALT and AST, were also consistently observed, with average decreases of 25% and 20% respectively (p<0.001).
Why It Matters
This comprehensive meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in treating both MASLD and MASH, addressing a critical unmet medical need. The significant rates of MASH resolution and fibrosis improvement suggest these therapies could fundamentally alter the disease trajectory for millions of patients. These findings strongly support the potential for GLP-1 RAs to become a cornerstone pharmacological treatment for MASLD and MASH, moving beyond their current indications for diabetes and obesity. Future large-scale Phase III clinical trials specifically designed for MASH endpoints are warranted to further solidify these findings and pave the way for regulatory approvals.